AXSOME THERAPEUTICS INCAXSM
ASignal's systematic analysis rates AXSM as Bearish.
Reflects the latest available analysis · analyzed Oct 15, 2026
The case on AXSM
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong revenue growth (45.5% YoY)
- High gross margin (93.24%) indicating pricing power
- Cash position exceeds total debt ($319.85M vs $224.69M)
- RSI at 12.94 suggests deep oversold conditions
- Negative operating and net margins
- Negative free cash flow and operating cash flow
- High debt-to-equity ratio (2.70x)
- Negative ROE (-245.10%) and negative ROA (-16.31%)
- EV/EBITDA of -48.59x indicates unprofitability
- No Reddit mentions, limited retail sentiment data
See the full verdict on AXSM
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes AXSM
Most investors never get a second opinion, let alone several. ASignal runs AXSM past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.